Purple Biotech Exercises Warrants For $2M Gross Proceeds
Purple Biotech Exercises Warrants For $2M Gross Proceeds
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3 (File Nos. 333-268710, 333-235327 and 333-215037). The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions.
世代生物科技有限公司（“紫色生物科技”或“公司”）（納斯達克/特拉維夫證券交易所：PPBT），一家正在開發首個治療方案以克服腫瘤免疫逃避和藥物抵抗的臨床前公司，今天宣佈，已與具體協議達成一致，行使某些現有認股權證，購買5,633,509美國存托股票（ADS），每股代表10股普通股，最初的行使價格範圍爲每股1.25-20.00美元，於2023年10月、2020年6月、2019年1月和2018年6月由紫色生物科技發行，以降低的行使價格每ADS 0.36美元行使。ADS的發行和/或再銷售，按照相關法規對於有效註冊的申明書所陳述，而此次發行預計於2024年7月2日左右關閉，須滿足慣常的交割條件。
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
H.C.Wainwright & Co.將擔任本次定向增發的獨家配售代理。